Imatinib in Canine Mast Cell Tumor Care: Extra-Label Evidence Review

Imatinib has published canine mast cell tumor experience but is not interchangeable with veterinary-labeled TKIs and requires specialist, legal, formulation, and evidence review.

Imatinib is an oral small-molecule TKI developed for human medicine. Veterinary oncologists have reported use in selected canine mast cell tumors, often in complex or rescue settings.

It may be discussed when tumor biology, prior treatment, access, patient factors, and alternatives justify extra-label consideration. The veterinarian must specify product source, monitoring, handling, and legal framework.

Suitability depends on diagnosis, anatomy, molecular or label criteria where applicable, prior treatment, access, and the intended local or systemic goal. A named modality is not a promise of response and should be compared with surgery, conventional chemotherapy, radiation, or comfort-focused care.

A veterinary oncologist or radiation oncologist should define eligibility, treatment intent, current regulatory or licensing status in the relevant country, monitoring, expected burdens, and alternatives. Product labels and local rules take precedence over summaries.

Recent retrospective and smaller comparative canine studies report clinical activity but emphasize limited sample size, heterogeneous cases, and need for further safety and efficacy definition. The current FDA list of dog cancer drugs does not make imatinib a veterinary-labeled cancer product.

Gastrointestinal, blood-cell, liver, fluid, skin, or other effects and drug interactions may occur; compounded or human products can create formulation and supply questions. Human oncology instructions are not a canine prescription.

Risks vary widely across radiation fields, oral targeted medicines, biologics, and intratumoral procedures. Do not transfer instructions between modalities or countries, and do not assume that a biomarker, license, or commercial availability proves benefit for an individual patient.